151 related articles for article (PubMed ID: 21240382)
1. Expression of molecular markers in the tumor and survival prognosis in osteosarcoma.
Boulytcheva IV; Soloviev YN; Kushlinskii NE; Mahson AN
Bull Exp Biol Med; 2010 Dec; 150(2):237-42. PubMed ID: 21240382
[TBL] [Abstract][Full Text] [Related]
2. Investigating the Relationship between of Vascular Endothelial Growth Factor and HER-2neu in IHC Staining with Metastasis and Mortality in Patients with Osteosarcoma.
Aznab M; Khajevand Ahmady M; Jamshidi K; Madani SH; Khazaei S; Shoushtaryzadeh T; Bagheri A
Asian Pac J Cancer Prev; 2020 Oct; 21(10):3005-3009. PubMed ID: 33112560
[TBL] [Abstract][Full Text] [Related]
3. Expression of HER2/erbB-2 correlates with survival in osteosarcoma.
Gorlick R; Huvos AG; Heller G; Aledo A; Beardsley GP; Healey JH; Meyers PA
J Clin Oncol; 1999 Sep; 17(9):2781-8. PubMed ID: 10561353
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of expression of VEGF and Cox-2 in nasopharyngeal carcinoma and its association with expression of C-erbB2 and EGFR.
Kim TJ; Lee YS; Kang JH; Kim YS; Kang CS
J Surg Oncol; 2011 Jan; 103(1):46-52. PubMed ID: 21031415
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of bax, bcl-2, and p53 staining in primary osteosarcoma.
Kaseta MK; Khaldi L; Gomatos IP; Tzagarakis GP; Alevizos L; Leandros E; Papagelopoulos PJ; Soucacos PN
J Surg Oncol; 2008 Mar; 97(3):259-66. PubMed ID: 18161867
[TBL] [Abstract][Full Text] [Related]
6. Her-2/neu, p-53, and their coexpression in osteosarcoma.
Bakhshi S; Gupta A; Sharma MC; Khan SA; Rastogi S
J Pediatr Hematol Oncol; 2009 Apr; 31(4):245-51. PubMed ID: 19346874
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of tumor suppressors in osteosarcoma before and after neoadjuvant chemotherapy.
Robl B; Pauli C; Botter SM; Bode-Lesniewska B; Fuchs B
BMC Cancer; 2015 May; 15():379. PubMed ID: 25956431
[TBL] [Abstract][Full Text] [Related]
8. Clinicopathologic analysis of HER-2/neu immunoexpression among various histologic subtypes and grades of osteosarcoma.
Kilpatrick SE; Geisinger KR; King TS; Sciarrotta J; Ward WG; Gold SH; Bos GD
Mod Pathol; 2001 Dec; 14(12):1277-83. PubMed ID: 11743051
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of P-glycoprotein, HER-2/ErbB-2, p53, and Bcl-2 in primary tumor and metachronous lung metastases in patients with high-grade osteosarcoma.
Ferrari S; Bertoni F; Zanella L; Setola E; Bacchini P; Alberghini M; Versari M; Bacci G
Cancer; 2004 May; 100(9):1936-42. PubMed ID: 15112275
[TBL] [Abstract][Full Text] [Related]
10. COX-2 expression in DCIS: correlation with VEGF, HER-2/neu, prognostic molecular markers and clinicopathological features.
Perrone G; Santini D; Vincenzi B; Zagami M; La Cesa A; Bianchi A; Altomare V; Primavera A; Battista C; Vetrani A; Tonini G; Rabitti C
Histopathology; 2005 May; 46(5):561-8. PubMed ID: 15842638
[TBL] [Abstract][Full Text] [Related]
11. Transferrin receptor-1 and VEGF are prognostic factors for osteosarcoma.
Wu H; Zhang J; Dai R; Xu J; Feng H
J Orthop Surg Res; 2019 Sep; 14(1):296. PubMed ID: 31484533
[TBL] [Abstract][Full Text] [Related]
12. Expressions of p53, c-MYC, BCL-2 and apoptotic index in human osteosarcoma and their correlations with prognosis of patients.
Wu X; Cai ZD; Lou LM; Zhu YB
Cancer Epidemiol; 2012 Apr; 36(2):212-6. PubMed ID: 21890444
[TBL] [Abstract][Full Text] [Related]
13. Her-2/neu expression in osteosarcoma increases risk of lung metastasis and can be associated with gene amplification.
Zhou H; Randall RL; Brothman AR; Maxwell T; Coffin CM; Goldsby RE
J Pediatr Hematol Oncol; 2003 Jan; 25(1):27-32. PubMed ID: 12544770
[TBL] [Abstract][Full Text] [Related]
14. Cell surface expression of epidermal growth factor receptor and Her-2 with nuclear expression of Her-4 in primary osteosarcoma.
Hughes DP; Thomas DG; Giordano TJ; Baker LH; McDonagh KT
Cancer Res; 2004 Mar; 64(6):2047-53. PubMed ID: 15026342
[TBL] [Abstract][Full Text] [Related]
15. A systematic review of vascular endothelial growth factor expression as a biomarker of prognosis in patients with osteosarcoma.
Chen D; Zhang YJ; Zhu KW; Wang WC
Tumour Biol; 2013 Jun; 34(3):1895-9. PubMed ID: 23589053
[TBL] [Abstract][Full Text] [Related]
16. Relationships between levels of CXCR4 and VEGF and blood-borne metastasis and survival in patients with osteosarcoma.
Lin F; Zheng SE; Shen Z; Tang LN; Chen P; Sun YJ; Zhao H; Yao Y
Med Oncol; 2011 Jun; 28(2):649-53. PubMed ID: 20349215
[TBL] [Abstract][Full Text] [Related]
17. HER-2/neu and p53 in osteosarcoma: an immunohistochemical and fluorescence in situ hybridization analysis.
Tsai JY; Aviv H; Benevenia J; Chang VT; Patterson F; Aisner S; Hameed M
Cancer Invest; 2004; 22(1):16-24. PubMed ID: 15069760
[TBL] [Abstract][Full Text] [Related]
18. Expression of cyclooxygenase-2 in breast carcinogenesis and its relation to HER-2/neu and p53 protein expression in invasive ductal carcinoma.
Cho MH; Yoon JH; Jaegal YJ; Choi YD; Lee JS; Lee JH; Nam JH; Choi C; Lee MC; Park CS; Woo Juhng S; Min KW
Breast; 2006 Jun; 15(3):390-8. PubMed ID: 16169726
[TBL] [Abstract][Full Text] [Related]
19. HER-2 expression is not prognostic in osteosarcoma; a Children's Oncology Group prospective biology study.
Gorlick S; Barkauskas DA; Krailo M; Piperdi S; Sowers R; Gill J; Geller D; Randall RL; Janeway K; Schwartz C; Grier H; Meyers PA; Gorlick R; Bernstein M; Marina N
Pediatr Blood Cancer; 2014 Sep; 61(9):1558-64. PubMed ID: 24753182
[TBL] [Abstract][Full Text] [Related]
20. Expression of HER-2/neu, epidermal growth factor receptor, vascular endothelial growth factor, cyclooxygenase-2, estrogen receptor, and progesterone receptor in small cell and large cell neuroendocrine carcinoma of the uterine cervix: a clinicopathologic and prognostic study.
Tangjitgamol S; Ramirez PT; Sun CC; See HT; Jhingran A; Kavanagh JJ; Deavers MT
Int J Gynecol Cancer; 2005; 15(4):646-56. PubMed ID: 16014119
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
